Catch up on today’s top five analyst upgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Buy from Neutral at UBS with analyst Michael Leuchten viewing the shares as attractively valued relative to the company’s growth profile. 2. Nike (NKE) upgraded to Buy from Hold at HSBC with analyst Erwan Rambourg noting that top line growth and margin expansion are no longer mutually exclusive for the company as online sales and DTC business “kick in sustainably.” 3. Square (SQ) upgraded to Buy from Neutral at Guggenheim with analyst Jeff Cantwell saying the response in shares over the past two days is largely a near-term momentum-driven negative reaction to this week’s decline in the price of Bitcoin, presenting an opportunity to buy Square following “strong” Q4 results. 4. Lowe’s (LOW) upgraded to Buy from Accumulate at Gordon Haskett with analyst Chuck Grom saying he is more confident now that he was when he had previously downgraded the stock in November in Lowe’s ability to “stomp the comp” in 2021 given both company specific efforts and today’s “very favorable” macro and housing backdrop. 5. Mattel (MAT) upgraded to Buy from Neutral at Monness Crespi with analyst Jim Chartier saying the stock’s risk/reward is favorable as cost savings and strong sales momentum provide good visibility to “meaningful” EBITDA growth over the next three years. This list is just a portion of The Fly’s full analyst coverage. To see The Fly’s full Street Research coverage, (click here.):(http://thefly.com/streetResearch.php)
previous post
next post